Across TCGA pan-cancer cohorts, LITAF Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LITAF data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher LITAF Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LITAF expression acts as an unfavorable survival marker.

COAD and SKCM are the cancer types where LITAF Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.181	0.806	.002	6	view →
SKCM	OS	Median	All	0.301	0.786	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: LITAF tumor-vs-normal RNA expression · all LITAF data types